View Older Stories View More Recent Stories

Oct 21, 2024 02:00AM PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round
Oct 9, 2024 02:00AM PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
Oct 1, 2024 07:00AM PureTech to Present at CHEST 2024 Annual Meeting
Sep 27, 2024 06:54AM PureTech Health Plc (PRTC) -Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Sep 27, 2024 02:00AM PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
Sep 6, 2024 02:00AM PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
Aug 28, 2024 02:01AM PureTech Health plc – Half-Year Report
Aug 22, 2024 02:00AM PureTech Appoints Michele Holcomb, PhD, to Board of Directors
Aug 21, 2024 02:00AM PureTech Health: Notice of Half-Yearly Results
Aug 13, 2024 07:06AM PureTech Health-founded (PRTC) Seaport Therapeutics Appoints David Wheadon to its Board
Aug 13, 2024 07:05AM PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors
Jul 23, 2024 08:26AM PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
Jun 24, 2024 12:00PM PureTech Health: Completion of Tender Offer & Total Voting Rights
Jun 24, 2024 02:00AM PureTech Health: Results of the Tender Offer
Jun 20, 2024 05:45AM PureTech Health Plc (PRTC) Appoints Raju Kucherlapati as Board Chair
Jun 20, 2024 02:00AM PureTech Announces Change of Board Role
Jun 18, 2024 07:06AM PureTech Health Plc (PRTC) Founded Entity Seaport Therapeutics Appoints Management Executives
Jun 18, 2024 07:05AM PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
Jun 13, 2024 01:15PM PureTech Health: Results of Annual General Meeting
Jun 6, 2024 12:38PM PureTech Health: Result of General Meeting
May 29, 2024 08:09AM PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company
May 23, 2024 07:00AM PureTech to Present at the Jefferies Global Healthcare Conference
May 21, 2024 07:05AM PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
May 20, 2024 02:00AM PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
May 9, 2024 07:05AM PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
May 7, 2024 07:05AM PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
Apr 25, 2024 05:22AM PureTech Announces Annual Results for Year Ended December 31, 2023
Apr 18, 2024 02:00AM PureTech Health: Notice of Results
Apr 16, 2024 07:00AM PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
Apr 11, 2024 07:00AM PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
Apr 9, 2024 02:00AM PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
Mar 19, 2024 04:14AM PureTech Health Plc (PRTC) Announces Proposed $100M Capital Return
Mar 19, 2024 03:00AM PureTech Proposes $100 Million Capital Return
Mar 18, 2024 09:52AM Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
Mar 13, 2024 07:01AM PureTech Health (PRTC) Receives Orphan Drug Designation for LYT-200
Mar 13, 2024 07:00AM PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
Feb 27, 2024 07:00AM PureTech to Present at Two Upcoming Investor Conferences
Feb 27, 2024 05:57AM PureTech-Founded (PRTC) Akili (AKLI) Reports Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx
Feb 27, 2024 02:00AM PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Jan 3, 2024 07:00AM PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
Dec 22, 2023 09:13AM PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Dec 20, 2023 03:56AM PureTech Health Plc (PRTC) Issues Year End Update and Outlook for 2024
Dec 20, 2023 02:00AM PureTech Year End Update and Outlook for 2024
Dec 7, 2023 06:00AM PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
Nov 29, 2023 10:18AM PureTech Health (PRTC) Founded Entity Karuna Therapeutics (KRTX) Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Nov 29, 2023 10:17AM PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
Nov 17, 2023 05:37AM PureTech Health (PRTC) Reports Karuna's (KRTX) Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Nov 17, 2023 02:00AM PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Nov 14, 2023 03:49AM PureTech Health (PRTC) Reports LYT-300 Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
Nov 14, 2023 02:00AM PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
View More Recent Stories View Older Stories